One-Year Real-World Outcomes of Switching to Aflibercept 8 mg in Eyes with Neovascular Age-Related Macular Degeneration: A Swiss Retina Research Network Report
In pretreated nAMD eyes with high treatment demand, switching to Afl 8 resulted in a significant anatomical improvement and longer treatment intervals in a majority of patients. These real-world results highlight the therapeutic potential of Afl 8, with no new or unexpected safety issues.
Authors
- Christin Schild (ORCID: https://orcid.org/0000-0001-7705-1103)
- Simon Magnin
- Moreno Menghini (ORCID: https://orcid.org/0000-0002-1432-2524)
- Sandrine Zweifel (ORCID: https://orcid.org/0000-0001-7431-1774)
- Gábor Márk Somfai (ORCID: https://orcid.org/0000-0001-6329-442X)
- Chiara Maria Eandi (ORCID: https://orcid.org/0000-0003-3656-1689)
- Isabel B. Pfister (ORCID: https://orcid.org/0000-0001-8752-8390)
- Anne Tillmann
- Katja Hatz
- Marion Rohit Munk
- Tahm Spitznagel
- Nicolò Bartolomeo (ORCID: https://orcid.org/0000-0001-9522-7176)
- Felix Gabathuler
- Aude Ambresin
- Katharina Heck
- Alice M. Kitay
- Matteo Bonanata
- Nicolas Feltgen
- Jordan Löliger
- Andreas Weinberger
- Malaika M. Kurz-Levin
- Justus G. Garweg
Institutions
- Semmelweis University (HU)
- Northwestern University (US)
- University Hospital of Basel (CH)
- Hôpital Ophtalmique Jules-Gonin (CH)
- Berner Augenklinik am Lindenhofspital (CH)
- Ente Ospedaliero Cantonale (CH)
- University Hospital of Zurich (CH)
- Universitätsklinik für Augenheilkunde (CH)
- Vista Klinik (CH)
- Kantonsschule Olten (CH)
- Stadtspital Waid (CH)
- Orthopädische Praxis (DE)
- Immunologie-Zentrum Zürich (CH)
- University of Turin (IT)
Publication Details
- Journal
- Ophthalmology and Therapy
- Published
- 2026-03-04
- DOI
- https://doi.org/10.1007/s40123-026-01344-x
- Primary Topic
- Retinal Diseases and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Allergan